Aslan Pharmaceuticals Limited (ASLN)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Aslan Pharmaceuticals Limited announced operating deficit of $-47.882487 millions, in the fourth quarter of 2022
company delivered fourth quarter of 2022 operating deficit of $-47.882487 millions
Published Mar 26 2023
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
While the earnings season of the October to December 31 2022 continues, the most businesses have announced the results. Some of them, are various entities in the Biotechnology & Pharmaceuticals industry. And today, ASLN reported operating deficit of $-47.882487 millions, for the most recent fiscal period. The operating deficit has depleted from $-33.846452 millions, from the fourth quarter of 2021. But more importantly, the investors are speculating, when the ASLNs' may start to report the revenue.
It is not really a surprise, that the rising firm recorded a net loss of $-51.382 millions, that has swelled from $-31.591 millions, in the same three months a preceding year.
the Biotechnology & Pharmaceuticals company announced shortfall of $-51.38 millions and Revenues of $0.00 millions in the financial period 2022.
Net shortfall per share has widen to $-0.15 from $-0.10 in preceding financial year, while by 0 % from $0.00 millions a year before.
Aslan Pharmaceuticals Limited is expected to report next financial results on March 23, 2024.